Merrill keeps ICOS at neutral

ICOS Corp. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende. U.S. Cialis sales of $82 million were in line with Merrill's estimate, with worldwide sales of $223 million beating the analyst's estimate of $215 million. While waiting for the company's first-quarter report, Merrill is increasing its full-year worldwide Cialis sales estimate to $915 million from $882 million. Shares of the Bothell, Wash., biotechnology company were down 3 cents, or 0.13%, at $23.05 on volume of 1,226,520 shares versus the three-month running average of 906,303 shares. (Nasdaq: ICOS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.